|
Garcia, D E; Brown, S; Hille, B et al. (1998) Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci 18:2834-41
|
|
Felder, C C; Joyce, K E; Briley, E M et al. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284:291-7
|
|
Garcia, D E; Li, B; Garcia-Ferreiro, R E et al. (1998) G-protein beta-subunit specificity in the fast membrane-delimited inhibition of Ca2+ channels. J Neurosci 18:9163-70
|
|
Felder, C C; Joyce, K E; Briley, E M et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-50
|
|
Priller, J; Briley, E M; Mansouri, J et al. (1995) Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors. Mol Pharmacol 48:288-92
|
|
Mackie, K; Lai, Y; Westenbroek, R et al. (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552-61
|
|
Felder, C C; Briley, E M; Axelrod, J et al. (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A 90:7656-60
|
|
Mackie, K; Devane, W A; Hille, B (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 44:498-503
|
